ClinicalTrialsFinder

Corticosteroid-refractory Chronic Graft vs. Host Disease Clinical Trials in Beijing

1 recruitingBeijing, China

Showing 1–1 of 1 trials

Recruiting
Phase 4

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

Graft vs Host DiseaseChronic Graft vs. Host DiseaseCorticosteroid-refractory Chronic Graft vs. Host Disease
Novartis Pharmaceuticals50 enrolled19 locationsNCT06824103